We have updated our Privacy Policy effective October 14, 2024. Please review the Privacy Policy closely.

Leaders in Fertility Research

Reproductive Medicine Associates (RMA) has been a pioneer in fertility science since its inception in 1999, with an unwavering commitment to improving patient outcomes.

rma research

Research & Innovation

Over the years RMA has evolved to become one of the most trusted authorities on all aspects of infertility, including research, education and patient care. This unparalleled emphasis on research and innovation has made possible quantum leap advancements in the practice of In Vitro Fertilization (IVF) that have given rise to a new standard of care for the industry and a new benchmark of success for patients.

Raising the Bar

Today, due to advancements encouraging Single Embryo Transfer (SET), IVF with RMA means a drastic reduction in multiple births resulting in a lower risk for mothers and babies. RMA’s singleton babies are now born with the same weight and term delivery rates as those conceived naturally.

steps of ivf
infertile couple

Improving Outcomes

How has RMA reduced the burden of care so quickly? By investing tens of millions of dollars into studying one question: how can IVF lead to one healthy baby?

The answer required getting several steps exactly right, and each clinical trial done at RMA inched doctors closer to finding the answer. Still, everyday doctors at RMA are working to further advance the field, finding answers to new questions that can improve outcomes and help couples complete their families safely and in the shortest time possible.

With a state-of-the-art laboratory, embryologists, scientists, and doctors as passionate as they are skilled, and a tireless focus on discovery, RMA is a worldwide leader in turning ideas into science, science into success, and success into families.

Research Oriented

RMA’s research has spanned the field of assisted reproduction and sought to make new discoveries in the areas of diminished ovarian reserve, endometriosis, Polycystic Ovary Syndrome (PCOS), male fertility, egg freezing, embryo biopsy, and testing, mosaicism, the microbiome, fibroids, stem cell rejuvenation, extended embryo culture, and dozens of more topics.

RMA’s April 2017 merger with IVI, Europe’s biggest IVF provider, has only elevated the group’s scientific reach. Together, IVI-RMA Global is the single-biggest investor in IVF research in the world.

genetic testing fertilty treatment

Published Research

Since its founding in 1999, RMA has published hundreds of pieces of research – including more than a dozen clinical trials – in an effort to improve patient outcomes.

Below is a non-exhaustive list of published works. To learn about IVI-RMA Global’s research, visit our Innovation website at ivi-rmainnovation.com.

2024
PROVA Study (PRP for Ovarian Activation: an RCT)

This prospective randomized control trial showed that, in women with a history of poor ovarian response, intraovarian platelet rich plasma injection (PRP) did not improve the number of mature eggs obtained at the egg retrieval procedure compared to participants who did not receive the PRP injection procedure. Additionally, in those participants who obtained mature egg(s), they were not any more likely to create a blastocyst(s) stage embryo, have chromosomally normal blastocyst stage embryo(s) available for transfer, or have any increase in their likelihood of achieving pregnancy.

Does Recurrent Implantation Failure (RIF) exist?

This retrospective study built upon the work by Pirtea et al (see Pirtea RIF study) and showed that in patients who have 5 chromosomally normal blastocyst stage embryos available for transfer that 98% of patients cumulatively will achieve a live birth. This study was unique because it sought to determine the prevalence of RIF in the infertile population and was able to look for RIF in over 123,000 patients to determine that the vast majority of patients end up delivering after 5 chromosomally normal, single, embryo transfers.

2021
Rate of True Recurrent Implantation Failure Is Low

This retrospective study determined that in patients who have at least 3 chromosomally normal embryos available for transfer, cumulatively, 95% of patients will be discharged from care at RMA to their obstetrician and approximately 93% will deliver. This study suggests that RIF is rare and the majority of patients who have at least 3 chromosomally normal embryos available for transfer will deliver.

2020
PROVET Study (The Predictive Value of Embryo Testing)

The study validated the preimplantation genetic testing for aneuploidy (PGT-A) platform at Juno, which is the reference lab that performs the majority of PGT-A at RMA. This study determined that when this platform calls an embryo, “abnormal,” meaning that it has either missing or additional chromosomes, that the test is accurate in doing so. Furthermore, this study updated our ability to look at the impact of the embryo biopsy procedure and continued to illustrate that the procedure at RMA is not harmful to embryos.

2017
LO2 Phase I

A paired randomized controlled trial (RCT) comparing blastulation rate in ultra-low (2%) vs. low (5%) oxygen in extended culture (EC). *Preliminary research showed embryos prefer naturally-shifting culture oxygen levels to grow.

Speak to a Fertility Specialist & Get Started

Submit the form for an appointment. For immediate new patient scheduling, call 866-762-3140.

Call to ScheduleRequest We Call You
Schedule Your First Visit866-762-3140

Existing patients with inquiries, please call your local office or send a message via the Artemis Patient Portal.